Bortezomib for the treatment of previously untreated multiple myeloma

Immunotherapy

Volumn 5, Issue 4, 2013, Pages 327-352

  Romano, Alessandra ^a,b   Conticello, Concetta ^b   Di Raimondo, Francesco ^a,b  

^a UNIVERSITY OF CATANIA   (Italy)

^b Hematology Division   (Italy)

Author keywords

bortezomib; induction therapy; multiple myeloma

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; MELPHALAN; OSTEOCLAST DIFFERENTIATION FACTOR; PREDNISONE; THALIDOMIDE; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOGENETICS; DISEASE CONTROL; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HERPES ZOSTER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNFOLDED PROTEIN RESPONSE; VIRUS REACTIVATION;

BORONIC ACIDS; DRUG EVALUATION; HUMANS; MULTIPLE MYELOMA; PROTEASOME INHIBITORS; PYRAZINES; REMISSION INDUCTION;

EID: 84875959497     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.14     Document Type: Review

References (131)

1. Rajkumar SV, Buadi F. Multiple myeloma: New staging systems for diagnosis, prognosis and response evaluation. Best Pract. Res. Clin. Haematol. 20(4), 665-680 (2007).
2. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 87(1), 78-88 (2012).
3. Rajkumar SV. Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? Hematol. Am. Soc. Hematol. Educ. Program 2012, 354-361 (2012).
4. Greipp PR, San Miguel JF, Durie BG et al. International staging system for multiple myeloma. J. Clin. Oncol. 23(15), 3412-3420 (2005).
5. Kumar SK, Mikhael JR, Buadi FK et al. Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin. Proc. 84(12), 1095-1110 (2009).
6. Rajkumar SV. Treatment of multiple myeloma. Nat. Rev. Clin. Oncol. 8(8), 479-491 (2011).
7. Kumar SK, Lacy MQ, Dispenzieri A et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 118(6), 1585-1592 (2012).
8. Cavo M, Rajkumar SV, Palumbo A et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117(23), 6063-6073 (2011).
9. Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 20(9), 1467-1473 (2006).
10. Nooka AK, Kaufman JL, Behera M et al. The improved efficacy of bortezomib containing induction regimens (BCIR) versus non-bortezomib containing induction regimens (NBCIR) in transplant-eligible patients with multiple myeloma (MM): Metaanalysis of Phase III randomized controlled trials (RCTs). Presented at: 53rd American Society of Hematology Annual Meeting and Exposition. San Diego, CA, USA, 10-13 December 2011 (Abstract 3994).
11. Wang A, Duan Q, Liu X et al. (Bortezomib plus lenalidomide/thalidomide)- vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: A metaanalysis of randomized controlled trials. Ann. Hematol. 91(11), 1779-1784 (2012).
12. Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: A clash of philosophies. Blood 118(12), 3205-3211 (2011).
13. Morgan GJ, Gregory WM, Davies FE et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and meta-analysis. Blood 119(1), 7-15 (2012).
14. Sonneveld P, Schmidt-Wolf I, van der Holt B et al. HOVON-65/GMMG-HD4 randomized Phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Presented at: 53rd American Society of Hematology Annual Meeting and Exposition. San Diego, CA, USA, 10-13 December 2011 (Abstract 40).
15. Sonneveld P, Schmidt-Wolf IG, van der Holt B et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized Phase III HOVON-65/GMMG-HD4 trial. J. Clin. Oncol. 30(24), 2946-2955 (2012).
16. Niesvizky R, Flinn IW, Rifkin R et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: Results from all randomized patients in the community-based, Phase 3b UPFRONT study. Blood 118(21), Abstract 478 (2011).
17. Mateos MV, Oriol A, Martinez-Lopez J et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial. Lancet Oncol. 11(10), 934-941 (2010).
18. Chari A, Mazumder A, Jagannath S. Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics 4, 273-287 (2010).
19. Kane RC, Farrell AT, Sridhara R, Pazdur R. United States food and drug administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res. 12(10), 2955-2960 (2006).
20. Hamilton AL, Eder JP, Pavlick AC et al. Proteasome inhibition with bortezomib (PS-341): A Phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J. Clin. Oncol. 23(25), 6107-6116 (2005).
21. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22(2), 304-311 (2004).
22. Adams J. Proteasome Inhibitors in Cancer Therapy. Humana Press Inc., NJ, USA (2004).
23. Richardson PG, Barlogie B, Berenson J et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348(26), 2609-2617 (2003).
24. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352(24), 2487-2498 (2005).
25. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr. Cancer Drug Targets 11(3), 239-253 (2011).
26. Cao B, Mao X. The ubiquitin-proteasomal system is critical for multiple myeloma: Implications in drug discovery. Am. J. Blood Res. 1(1), 46-56 (2011).
27. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol. Cancer Ther. 10(11), 2034-2042 (2011).
28. Di Raimondo F, Conticello C. Captivating bortezomib: An active but still mysterious drug. Leuk. Res. 34(4), 411-412 (2010).
29. Conticello C, Giuffrida R, Adamo L et al. NF-kappaB localization in multiple myeloma plasma cells and mesenchymal cells. Leuk. Res. 35(1), 52-60 (2011).
30. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107(12), 4907-4916 (2006).
31. Hideshima T, Ikeda H, Chauhan D et al. Bortezomib induces canonical nuclear factorkappaB activation in multiple myeloma cells. Blood 114(5), 1046-1052 (2009).
32. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res. 67(11), 5418-5424 (2007).
33. Dong H, Chen L, Chen X et al. Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells. Leuk. Lymphoma 50(6), 974-984 (2009).
34. Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. J. Natl Cancer Inst. 103(13), 1007-1017 (2011).
35. Aronson LI, Davies FE. DangER. Protein overload. Targeting protein degradation to treat myeloma. Haematologica 97(8), 1119-1130 (2012).
36. Hoang B, Benavides A, Shi Y, Frost P, Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. Mol. Cancer Ther. 8(7), 1974-1984 (2009).
37. Kawaguchi T, Miyazawa K, Moriya S et al. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal. Int. J. Oncol. 38(3), 643-654 (2011).
38. Roccaro AM, Hideshima T, Raje N et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 66(1), 184-191 (2006).
39. Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clin. Cancer Res. 17(6), 1278-1286 (2011).
40. Moschetta M, Di Pietro G, Ria R et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur. J. Cancer 46(2), 420-429 (2010).
41. Terpos E, Christoulas D, Kokkoris P et al. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann. Oncol. 21(7), 1561-1562(2010).
42. von Metzler I, Krebbel H, Hecht M et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 21(9), 2025-2034 (2007).
43. Gareau C, Fournier MJ, Filion C et al. p21(WAF1/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis. PLoS ONE 6(5), e20254 (2011).
44. Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC. Proteasome inhibitor therapy in multiple myeloma. Mol. Cancer Ther. 4(4), 686-692 (2005).
45. Piro E, Molica S. A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: What is the published evidence? Acta Haematol. 126(3), 163-168 (2011).
46. Lorusso PM, Venkatakrishnan K, Ramanathan RK et al. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: Phase I NCI organ dysfunction working group study NCI-Clin. Cancer Res. 18(10), 2954-2963 (2012).
47. Mutlu GM, Budinger GR, Wu M et al. Proteasomal inhibition after injury prevents fibrosis by modulating TGF-beta(1) signalling. Thorax 67(2), 139-146 (2012).
48. Gentilini F, Levi A, Federico V, Russo E, Foà R, Petrucci MT. Bortezomib a safe treatment for patients with multiple myeloma and cystic fibrosis. Mediterr. J. Hematol. Infect. Dis. 4(1), e2012035 (2012).
49. Venkatakrishnan K, Rader M, Ramanathan RK et al. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. Clin. Ther. 31(Pt 2), 2444-2458 (2009).
50. Quinn DI, Nemunaitis J, Fuloria J et al. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin. Pharmacokinet. 48(3), 199-209 (2009).
51. Kim TY, Park J, Oh B et al. Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction. Br. J. Haematol. 146(3), 270-281(2009).
52. Moreau P, Coiteux V, Hulin C et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 93(12), 1908-1911(2008).
53. Moreau P, Pylypenko H, Grosicki S et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, Phase 3, non-inferiority study. Lancet Oncol. 12(5), 431-440 (2011).
54. Moreau P, Karamanesht II, Domnikova N et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: Effects of subcutaneous injection site and concentration, and patient characteristics. Blood 118(21), Abstract 1863 (2011).
55. Jagannath S, Durie BG, Wolf JL et al. Extended follow-up of a Phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br. J. Haematol. 146(6), 619-626 (2009).
56. Jagannath S, Durie BG, Wolf J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br. J. Haematol. 129(6), 776-783 (2005).
57. Popat R, Oakervee HE, Hallam S et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: Updated results after long-term follow-up. Br. J. Haematol. 141(4), 512-516 (2008).
58. Oakervee HE, Popat R, Curry N et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Haematol. 129(6), 755-762 (2005).
59. Jakubowiak AJ, Griffith KA, Reece DE et al. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: A Phase 1/2 multiple myeloma research consortium trial. Blood 118(3), 535-543 (2011).
60. Jakubowiak AJ, Kendall T, Al-Zoubi A et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J. Clin. Oncol. 27(30), 5015-5022 (2009).
61. Harousseau JL, Attal M, Avet-Loiseau H et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 Phase III trial. J. Clin. Oncol. 28(30), 4621-4629 (2010).
62. Rosinol L, Cibeira MT, Mateos MV et al. A Phase III PETHEMA/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: Superiority of VTD (bortezomib/thalidomide/ dexamethasone) over TD and VBMCP/VBAD plus bortezomib. Blood 116(21), Abstract 307 (2010).
63. Cavo M, Pantani L, Petrucci MT et al. Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. Blood 120(1), 9-19 (2012).
64. Cavo M, Tacchetti P, Patriarca F et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised Phase 3 study. Lancet 376(9758), 2075-2085 (2010).
65. Moreau P, Avet-Loiseau H, Facon T et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118(22), 5752-5758; quiz 5982 (2011).
66. Richardson PG, Weller E, Lonial S et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5), 679-686 (2010).
67. Kumar S, Flinn I, Richardson PG et al. Randomized, multicenter, Phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119(19), 4375-4382 (2012).
68. Reeder CB, Reece DE, Kukreti V et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a Phase II clinical trial. Leukemia 23(7), 1337-1341 (2009).
69. Reeder CB, Reece DE, Kukreti V et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 115(16), 3416-3417 (2010).
70. Landau H, Pandit-Taskar N, Hassoun H et al. Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leuk. Lymphoma 53(2), 275-281 (2012).
71. Berenson JR, Yellin O, Chen CS et al. A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. Br. J. Haematol. 155(5), 580-587 (2011).
72. Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 12(3), 235-239 (2007).
73. Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: A retrospective study. Cancer 116(13), 3143-3151 (2010).
74. Palumbo A, Magarotto V, Gay F, Falco P, Bringhen S, Boccadoro M. Update on recent developments for patients with newly diagnosed multiple myeloma. Ann. NY Acad. Sci. 1138, 19-21 (2008).
75. SanMiguel J, Facon T, Cavo M. Recent Phase III trials in the frontline treatment of multiple myeloma: Evaluating their impact on community practice. Clin. Adv. Hematol. Oncol. 6(4), S4-S10 (2008).
76. Rosinol L, Oriol A, Mateos MV et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: Efficacy and clinical implications of tumor response kinetics. J. Clin. Oncol. 25(28), 4452-4458 (2007).
77. Rosinol L, Oriol A, Teruel AI et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized Phase 3 PETHEMA/GEM study. Blood 120(8), 1589-1596 (2012).
78. Kumar SK, Flinn I, Noga SJ et al. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: Phase 1 results from the multicenter EVOLUTION study. Leukemia (Engl.) 24(7), 1350-1356 (2010).
79. Reece DE. Posttransplantation maintenance therapy and optimal frontline therapy in myeloma. Hematology Am. Soc. Hematol. Educ. Program 2011, 197-204 (2011).
80. Bensinger WI, Jagannath S, Vescio R et al. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. Br. J. Haematol. 148(4), 562-568 (2010).
81. Kumar S, Giralt S, Stadtmauer EA et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 114(9), 1729-1735 (2009).
82. Moreau P, Hulin C, Marit G et al. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-2001 trial. Leukemia 24(6), 1233-1235 (2010).
83. Brioli A, Perrone G, Volpe S et al. Autologous peripheral blood stem-cell (PBSC) collection is not impaired by bortezomib-thalidomidedexamethasone (VTD) induction therapy in newly diagnosed multiple myeloma (MM). Blood 118(21), Abstract 317 (2011).
84. Lonial S, Kaufman J, Tighiouart M et al. A Phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: A dose- and schedule-finding study. Clin. Cancer Res. 16(20), 5079-5086 (2010).
85. Nishihori T, Ochoa L, Pidala J et al. A Phase 2 study of bortezomib plus high-dose Melphalan (Mel/Vel) conditioning for autologous hematopoietic cell transplantation in multiple myeloma. Blood. 118(21), Abstract 4158 (2011).
86. Roussel M, Moreau P, Huynh A et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: A Phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 115(1), 32-37 (2010).
87. Mellqvist UH, Westin J, Gimsing P et al. Improved response rate with bortezomib consolidation after high dose melphalan: First results of a nordic myeloma study group randomized Phase III trial. Presented at: 51st American Society of Hematology Annual Meeting and Exposition. New Orleans, LA, USA, December 5-8 2009 (Abstract 530).
88. Ladetto M, Pagliano G, Ferrero S et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J. Clin. Oncol. 28(12), 2077-2084 (2010).
89. Roussel M, Robillard N, Moreau P et al. Bortezomib, lenalidomide, and dexamethasone (VRD) consolidation and lenalidomide maintenance in frontline multiple myeloma patients: Updated results of the IFM 2008 Phase II VRD intensive program. Blood 118(21), Abstract 1872 (2011).
90. Rosinnol L, Oriol A, Teruel AI et al. Maintenance therapy after stem-cell transplantation for multiple myeloma with bortezomib/thalidomide vs thalidomide vs alfa2b-interferon: Final results of a Phase III PETHEMA/GEM randomized trial. Blood 120(21), Abstract 334 (2012).
91. Kumar A, Hozo I, Wheatley K, Djulbegovic B. Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: A systematic review. Am. J. Hematol. 86(1), 18-24 (2011).
92. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359(9), 906-917 (2008).
93. Palumbo A, Bringhen S, Rossi D et al. Bortezomib-melphalan- prednisonethalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial. J. Clin. Oncol. 28(34), 5101-5109 (2010).
94. Mateos MV, Oriol A, Martinez-Lopez J et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 120(13), 2581-2588 (2012).
95. Mateos MV, Richardson PG, Schlag R et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the Phase III VISTA trial. J. Clin. Oncol. 28(13), 2259-2266 (2010).
96. San Miguel JF, Schlag R, Khuageva NK et al. Continued overall survival benefit after 5 years' follow-up with bortezomibmelphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: Final results of the Phase 3 VISTA trial. Presented at: 53rd American Society of Hematology Annual Meeting and Exposition. San Diego, CA, USA, 10-13 December 2011 (Abstract 476).
97. Spicka I, Mateos MV, Redman K, Dimopoulos MA, Richardson PG. An overview of the VISTA trial: Newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation. Immunotherapy 3(9), 1033-1040 (2011).
98. Bringhen S, Larocca A, Rossi D et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116(23), 4745-4753 (2010).
99. Palumbo A, Sezer O, Kyle R et al. International myeloma working group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23(10), 1716-1730 (2009).
100. Romano A, Chiarenza A, Consoli U et al. Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma. Ann. Oncol. doi:10.1093/annonc/mds531 (2012) (Epub ahead of print).
101. Fernand JP, Facon T, Moreau P. 13th International Myeloma Workshop, Paris, France, May 3-6, 2011. Haematologica 96(Suppl. 1), S81 (2011) (Abstract P175).
102. Avet-Loiseau H, Leleu X, Roussel M et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol. 28(30), 4630-4634 (2010).
103. Cools J, Malcovati L, Camaschella C et al. 17th Congress of the European Hematology Association, Amsterdam, The Netherlands, June 14-17, 2012 (Abstract Book). Haematologica 97(Suppl. 1), 1-738 (2012).
104. Gertz MA, Kumar S, Lacy MQ et al. Stem cell transplantation in multiple myeloma: Impact of response failure with thalidomide or lenalidomide induction. Blood 115(12), 2348-2353; quiz 2560 (2010).
105. Moreau P, Attal M, Pegourie B et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-2001 trial. Blood 117(11), 3041-3044 (2011).
106. Awan FT, Osman S, Kochuparambil ST et al. Impact of response to thalidomide-, lenalidomide- or bortezomib-containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation. Bone Marrow Transplant. 47(1), 146-148 (2012).
107. Zamagni E, Patriarca F, Nanni C et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118(23), 5989-5995 (2011).
108. Terragna C, Remondini D, Durante S et al. A 41-gene signature predicts complete response (CR) to bortezomib-thalidomidedexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). Blood 118(21), Abstract 805 (2011).
109. Dickens NJ, Walker BA, Leone PE et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin. Cancer Res. 16(6), 1856-1864 (2010).
110. Broyl A, Hose D, Lokhorst H et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 116(14), 2543-2553 (2010).
111. Nair B, van Rhee F, Shaughnessy JD Jr et al. Superior results of total therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 115(21), 4168-4173 (2010).
112. Paiva B, Vidriales MB, Cerveró J et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112(10), 4017-4023 (2008).
113. Ling SC, Lau EK, Al-Shabeeb A et al. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica 97(1), 64-72 (2012).
114. Richardson PG, Sonneveld P, Schuster MW et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the Phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline. Br. J. Haematol. 144(6), 895-903 (2009).
115. Zangari M, Fink L, Zhan F, Tricot G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: Review of data from Phase 3 trials and studies of novel combination regimens. Clin. Lymphoma Myeloma Leuk. 11(2), 228-236 (2011).
116. Lonial S, Richardson PG, San Miguel JF et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br. J. Haematol. 143(2), 222-229 (2008).
117. Patriarca F, Petrucci MT, Bringhen S et al. Considerations in the treatment of multiple myeloma: A consensus statement from Italian experts. Eur. J. Haematol. 82(2), 93-105 (2009).
118. Palumbo A, Cavo M, Bringhen S et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A Phase III, open-label, randomized trial. J. Clin. Oncol. 29(8), 986-993 (2011).
119. Shen Y, Zhou X, Wang Z et al. Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma. Leuk. Res. 35(2), 147-151 (2011).
120. Chanan-Khan A, Sonneveld P, Schuster MW et al. Analysis of herpes zoster events among bortezomib-treated patients in the Phase III APEX study. J. Clin. Oncol. 26(29), 4784-4790 (2008).
121. Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 115(1), 229-232 (2009).
122. Harousseau JL, Palumbo A, Richardson PG et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: Analysis of the Phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 116(19), 3743-3750 (2010).
123. Mateos MV, Hernández JM, Hernández MT et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter Phase 1/2 study. Blood 108(7), 2165-2172 (2006).
124. Fenk R, Neubauer F, Bruns I et al. Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation. Blood 118(21), Abstract 4087 (2011).
125. Razavi P, Rand KA, Ailawadhi S. Trends in incidence and survival of multiple myeloma with second primary malignancy. Blood 118(21), Abstract 3958 (2011).
126. Razavi P, Patel G, Chanan-Khan A, Ailawadhi S. Variable risk of second primary malignancy in multiple myeloma patients of different ethnicities. Blood 118(21), Abstract 678 (2011).
127. San Miguel JF, Richardson PG, Orlowski RZ et al. Risk of second primary malignancies (SPMS) following bortezomib (BTZ)-based therapy: Analysis of four Phase 3 randomized controlled trials in previously untreated or relapsed multiple myeloma (MM). Presented at: 53rd American Society of Hematology Annual Meeting and Exposition. San Diego, CA, USA, 10-13 December 2011 (Abstract 2933).
128. Byrn SR, Tishmack PA, Milton MJ, van de Velde H. Analysis of two commercially available bortezomib products: Differences in assay of active agent and impurity profile. AAPS Pharm. Sci. Tech. 12(2), 461-467 (2011).
129. Buac D, Shen M, Schmitt S et al. From bortezomib to other inhibitors of the proteasome and beyond. Curr. Pharm. Des. (2012) (Epub ahead of print).
130. Lawasut P, Chauhan D, Laubach J et al. New proteasome inhibitors in myeloma. Curr. Hematol. Malig. Rep. 7(4), 258-266 (2012).
131. Munshi NC, Lee S, Kambhampati S et al. Interim results of an ongoing clinical study suggests efficacy and improved toxicity profile with once a week bortezomib with dexamethasone in newly diagnosed multiple myeloma patients with older age and comorbidities. Blood 116(21), Abstract 3061 (2010).